Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022;50(S1):24-28.
doi: 10.1017/jme.2022.31.

Pre-Exposure Prophylaxis for HIV Infection as a Public Health Tool

Chris Beyrer, Sheena McCormack, Andrew Grulich
Review

Pre-Exposure Prophylaxis for HIV Infection as a Public Health Tool

Chris Beyrer et al. J Law Med Ethics. 2022.

Abstract

The efficacy of pre-exposure prophylaxis, PrEP, with antiviral agents for prevention of HIV infection has been demonstrated in multiple randomized controlled trials and demonstration projects. These trials have studied prevention at the individual level. The effectiveness of PrEP as a public health intervention to reduce HIV incidence at community and population levels is being actively evaluated but is less well described. In reviewing the available data on PrEP as a public health intervention, three significant examples have demonstrated success, and all have been among communities of gay, bisexual and other men who have sex with men (MSM).

Keywords: HIV; Incidence; Pre-Exposure Prophylaxis; Public Health Tool.

PubMed Disclaimer

References

    1. Rakhmanina N.Y. and van den Anker J.N., “Pharmacologic Prevention of Perinatal HIV infection,” Early Human Development 90 (2014): S13–5. - PubMed
    1. Grant R.M., et al., “Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men,” New England Journal of Medicine 363 (2010): 2587–2599. - PMC - PubMed
    1. Centers for Disease Control and Prevention (CDC), “Oral Daily Pre-Exposure Prophylaxis (PrEP) for HIV-Negative Persons,” CDC, available at <https://www.cdc.gov/hiv/risk/estimates/preventionstrategies.html#anchor_...> (last visited March 18, 2022).
    1. Choopanya K., et al., “Antiretroviral Prophylaxis for HIV Infection in Injecting Drug Users in Bangkok, Thailand (the Bangkok Tenofovir Study): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial,” Lancet 381, no. 9883 (2013): 2083–90. - PubMed
    1. Marrazzo J.M., et al., “Pre-exposure Prophylaxis for HIV in Women: Daily Oral Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 003),” Conference on Retroviruses and Opportunistic Infections, Atlanta, March 3-6, 2013; published in NEJM 372, no. 6 (2015): 509. - PubMed

Publication types

Substances